Cencora Inc., US03073E1055

Cencora stock: FTC lawsuit puts MWI sale on court timetable

Published on 11/17/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora stock faces a federal challenge to its planned MWI Animal Health sale. The case could delay the transaction as proceedings move into court.

Deal faces a new legal hurdle

  • The FTC and 13 states seek to block Covetrus' proposed acquisition of MWI Animal Health.
  • The $3.5 billion transaction would give Cencora cash, preferred equity and a common-equity stake if completed.
  • The court process puts the transaction timetable and regulatory outcome at the center of investor attention.
Cencora Inc., US03073E1055, Illustration mit AI erstellt.

Cencora's planned sale of MWI Animal Health to Covetrus faces a federal antitrust challenge after the U.S. Federal Trade Commission and 13 states sued to block the transaction on Friday, November 13, 2026. The Philadelphia Inquirer reported that the complaint seeks to stop Covetrus' proposed $3.5 billion acquisition of Cencora's veterinary distribution business.

Cencora stock traded at 322.15 euros on Lang & Schwarz at 16:03 CET on Tuesday, November 17. Compared with 325.95 euros in our report of November 16, the latest quote shows a 1.17 percent change.

FTC challenges the proposed sale

The FTC alleges that Covetrus and MWI are two of the largest U.S. veterinary distributors. The agency says combining them could reduce competition, raise costs for veterinary clinics and increase prices for pet owners.

The complaint was filed in federal court in Manhattan, with attorneys general from 13 states joining the case. The FTC is seeking a permanent injunction, making the court process central to the transaction's next steps.

Deal terms remain in focus

Cencora agreed in February to sell MWI to privately held Covetrus. Under the proposed structure, Cencora would receive $1.25 billion in cash, $800 million in preferred equity and $1.45 billion in common equity, while retaining a 34 percent common-equity stake in the combined company.

Covetrus has challenged the FTC's market view, saying clinics can choose among numerous manufacturers and distributors and that online platforms have broadened purchasing options. The legal dispute now adds execution risk to the planned divestment and leaves the deal timetable subject to the court process.

U.S. healthcare shares trade against the broader market backdrop shown in Current market reports.

More news and analyses on Cencora stock.

Cencora company facts

  • Company: Cencora, Inc.
  • ISIN: US03073E1055
  • Ticker: COR
  • Home exchange: NYSE
  • Lang & Schwarz quote: 322.15 euros at 16:03 CET on November 17, 2026
Disclaimer...
en | US03073E1055 | CENCORA INC. | boerse | 70527523 | bgmi